TrialRMD open2025

Early effects of ozoralizumab 30 mg in patients with rheumatoid arthritis and inadequate response to methotrexate: a post hoc trajectory analysis of the phase II/III OHZORA trial.

Yusuke Miyazaki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.